Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05711524 · ClinicalTrials.gov registry record · Phase 4
Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding
A Phase 4 study of Bleeding and Hypofibrinogenemia, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 4
- Development phase
- 208
- Enrollment target
- 1
- Study location
NCT05711524: Completed Phase 4 study of Bleeding and Hypofibrinogenemia, sponsored by Weill Medical College of Cornell University.
NCT05711524 is a Phase 4 study of Bleeding and Hypofibrinogenemia that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 208 participants, below the 1,476-participant average among 23 other Bleeding trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05711524, a Phase 4 study of Bleeding and Hypofibrinogenemia, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 208 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this quality improvement study is to compare pathogen-reduced cryoprecipitate with traditional cryoprecipitate in liver transplant and cardiovascular patients. The investigators hypothesize that by having immediate access to a readily available thawed blood product that replaces fibrinogen (the main substrate of a blood clot), early bleeding can be treated before it escalates into uncontrolled hemorrhage, and therefore additional blood products, like platelets, plasma and red blood cells can be avoided. Participants will be given one of the two FDA-approved blood products.
Primary Outcome
RBCs used over admission
Conditions Studied
Interventions
- BIOLOGICAL Traditional Cryoprecipitate
- BIOLOGICAL Pathogen-Reduced Cryoprecipitate
Study Locations (1)
New York
- New York-Presbyterian Hospital/Weill Cornell Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2023-04-01 |
| Est. Completion | 2025-10-03 |
| Phase | Phase 4 |
What the finished NCT05711524 record still lists
NCT05711524 is an interventional study that assigns participants to a tested intervention. The registered 208 participants enrollment target is mid-sized for trials with a published cap, below the 1,476-participant average among 23 other Bleeding trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Bleeding appearing as the primary indexed condition, and to 2 interventions - of which Traditional Cryoprecipitate is the first listed.
NCT05711524 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05711524 about?
NCT05711524 is a clinical study titled "Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding". The goal of this quality improvement study is to compare pathogen-reduced cryoprecipitate with traditional cryoprecipitate in liver transplant and cardiovascular patients. The investigators hypothesize that by having immediate access to a readily available thawed blood product that replaces fibrinog...
What is the current status of trial NCT05711524?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 208 participants. The study started on 2023-04-01. Estimated completion is 2025-10-03.
What conditions does trial NCT05711524 study?
This clinical trial studies the following conditions: Bleeding, Hypofibrinogenemia.
What interventions are being tested in trial NCT05711524?
The interventions under investigation include: Traditional Cryoprecipitate (BIOLOGICAL), Pathogen-Reduced Cryoprecipitate (BIOLOGICAL).
Who is sponsoring clinical trial NCT05711524?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05711524 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bleeding
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05711524's enrollment target sits among peer trials
208 13th of 23 higher than 11 of 23 other Bleeding trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bleeding trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device
RECRUITING · Phase 4
-
Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users
COMPLETED · Phase 4
-
PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding
COMPLETED · Phase 4
-
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
RECRUITING · Phase 2
-
The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia
RECRUITING
-
Quantra Point-of-Care Hemostasis Monitoring
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465774 · 208 participants
Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
- NCT03803332 · 208 participants · NA
A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel
- NCT04732065 · 208 participants · Phase 1
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- NCT05293756 · 208 participants · NA
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI